• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TEM

    Tempus AI Inc.

    Subscribe to $TEM
    $TEM
    Computer Software: Programming Data Processing
    Technology

    IPO Year: 2024

    Exchange: NASDAQ

    Recent Analyst Ratings for Tempus AI Inc.

    DatePrice TargetRatingAnalyst
    10/21/2025$88.00Buy → Hold
    TD Cowen
    10/20/2025$110.00Buy
    Canaccord Genuity
    9/2/2025$90.00Buy
    H.C. Wainwright
    4/21/2025$60.00Buy
    BTIG Research
    2/25/2025$50.00 → $55.00Overweight → Neutral
    Analyst
    2/12/2025Outperform → Mkt Perform
    William Blair
    2/5/2025$58.00 → $74.00Buy
    TD Cowen
    12/13/2024$60.00Outperform
    Wolfe Research
    12/9/2024$74.00Buy
    Guggenheim
    11/11/2024$45.00 → $65.00Buy → Hold
    Stifel
    See more ratings

    Tempus AI Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Reporting)

    8/20/24 4:17:55 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempus to Report Third Quarter 2025 Financial Results on November 4

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 5436492 USA & Canada: Toll-Free (800) 715-9871 United States: Toll (646) 307-1963 Live Webcast: https://edge.media-server.com/mmc/p/vg3azega A

    10/21/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity

    Study finds significantly lower rates of provider-initiated exome reanalysis among diverse racial, ethnic, and ancestral groups highlighting the importance of proactive reanalysis offerings like Ambry's Patient for Life™ program Ambry Genetics, a leader in genetic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ:TEM), announced the publication of a peer-reviewed study in Genetics in Medicine (GIM), the official journal of the American College of Medical Genetics and Genomics (ACMG). The ACMG is a national organization bringing together experts in medical genetics to improve patient care and to support fair access to genetic services. The study presents a comprehensive ana

    10/20/25 9:00:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugates (ADC) cancer treatments. The collaboration aims to leverage Tempus' proprietary real-world dataset to advance biomarker-driven research and support the development of Whitehawk Therapeutics' oncology pipeline. Under the agreement, Whitehawk Therapeutics will apply Tempus' de-identified multimodal database to support the biotech's clinical trial

    10/16/25 8:30:00 AM ET
    $TEM
    $WHWK
    Computer Software: Programming Data Processing
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. "We're sharing research at ESMO Congress 2025, including two oral presentations, that highlight the growing role of real-world data and AI in developing more effective, personalized cancer treatments," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "These findings not only advance the development of new therapies but also equip clinicians with data-driven insights to guide patient

    10/15/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to provide testing and contract research organization (CRO) services in support of the agency's ADAPT (Advanced Analysis for Precision Cancer Therapy) program. The ADAPT program aims to revolutionize cancer treatment by developing adaptive strategies that leverage biomarkers to target metastatic disease, initially focusing on non-small cell lung, breast, and colorectal cancers, with the ultimate goal of improving patient

    10/9/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- Ohio State researchers recently solved a critical mystery explaining why some cancer immunotherapies fail[1], while a University of Chicago team discovered a common supplement that supercharges immune cells against tumors[2]. These breakthroughs are propelling the global cancer treatment market from $282 billion in 2025 toward $643.5 billion by 2034[3], creating powerful momentum for companies pioneering next-generation approaches including GT Biopharma, Inc. (NASDAQ:GTBP), Lexeo Therapeutics, Inc. (NASDAQ:LXEO), Anixa Biosciences, Inc. (NASDAQ:ANIX), Tempus AI, Inc. (NASDAQ:TEM)

    10/8/25 10:58:00 AM ET
    $ANIX
    $CTOR
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Computer Software: Programming Data Processing

    Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density

    The Ambry CARE Program® brings accurate, personalized breast cancer risk assessments directly into clinical workflows helping direct patients at high risk for breast cancer to seek additional screening Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ:TEM) and a pioneer in clinical genomic testing, today announced an enhancement to the Ambry CARE Program® (CARE), Ambry's digital platform that streamlines cancer risk assessment and genetic testing workflows. The update integrates breast density into the Tyrer-Cuzick (TC) breast cancer risk score within the electronic health record (EHR), providing clinicians with more precise and personalized risk estimates at the po

    10/1/25 12:24:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life sciences tool to support drug development programs. RNA sequencing captures a large array of biological information and offers deeper insights into the mechanisms of diseases, including enhanced fusion detection. RNA analysis is increasingly an important tool in research and development because it can identify molecular pathways and networks that are directly involved in disease progression. "We

    9/22/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

    MarketNewsUpdates News Commentary NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been experiencing significant growth due to the rising awareness about the benefits of cell therapies. They help regenerate damaged tissues and organs. They have the potential to treat a range of conditions, such as cancer, autoimmune diseases, infectious diseases, urinary issues, spinal cord injuries, joint cartilage damage, immune system weakness, and neurological disorders. Cell therapies target only damaged tissues, reducing the chances of getting damage to other tissues. Numerous cell types are

    9/18/25 8:45:00 AM ET
    $BMY
    $BNTX
    $CRSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Computer Software: Programming Data Processing

    Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease

    Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB:RNLXY), today announced an agreement with Tempus AI, Inc. (NASDAQ:TEM) to make kidneyintelX.dkd prognostic blood testing more widely available for eligible patients within its US network of healthcare institutions. Eligible patients have type 2 diabetes with chronic kidney disease, impacting nearly 15 million individuals in the US.

    9/15/25 8:00:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI Inc. SEC Filings

    View All

    SEC Form 144 filed by Tempus AI Inc.

    144 - Tempus AI, Inc. (0001717115) (Subject)

    9/25/25 7:04:21 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SCHEDULE 13D/A filed by Tempus AI Inc.

    SCHEDULE 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

    9/12/25 4:15:05 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 8-K filed by Tempus AI Inc.

    8-K - Tempus AI, Inc. (0001717115) (Filer)

    8/27/25 5:11:01 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 424B7 filed by Tempus AI Inc.

    424B7 - Tempus AI, Inc. (0001717115) (Filer)

    8/27/25 5:09:32 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 144 filed by Tempus AI Inc.

    144 - Tempus AI, Inc. (0001717115) (Subject)

    8/27/25 4:19:29 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 144 filed by Tempus AI Inc.

    144 - Tempus AI, Inc. (0001717115) (Subject)

    8/26/25 1:27:12 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 144 filed by Tempus AI Inc.

    144 - Tempus AI, Inc. (0001717115) (Subject)

    8/20/25 7:14:37 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form DEF 14C filed by Tempus AI Inc.

    DEF 14C - Tempus AI, Inc. (0001717115) (Filer)

    8/18/25 4:10:45 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form 144 filed by Tempus AI Inc.

    144 - Tempus AI, Inc. (0001717115) (Subject)

    8/18/25 2:44:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form PRE 14C filed by Tempus AI Inc.

    PRE 14C - Tempus AI, Inc. (0001717115) (Filer)

    8/8/25 4:04:58 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tempus AI downgraded by TD Cowen with a new price target

    TD Cowen downgraded Tempus AI from Buy to Hold and set a new price target of $88.00

    10/21/25 7:15:53 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Canaccord Genuity initiated coverage on Tempus AI with a new price target

    Canaccord Genuity initiated coverage of Tempus AI with a rating of Buy and set a new price target of $110.00

    10/20/25 8:04:09 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    H.C. Wainwright initiated coverage on Tempus AI with a new price target

    H.C. Wainwright initiated coverage of Tempus AI with a rating of Buy and set a new price target of $90.00

    9/2/25 8:40:58 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    BTIG Research initiated coverage on Tempus AI with a new price target

    BTIG Research initiated coverage of Tempus AI with a rating of Buy and set a new price target of $60.00

    4/21/25 8:39:11 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI downgraded by Analyst with a new price target

    Analyst downgraded Tempus AI from Overweight to Neutral and set a new price target of $55.00 from $50.00 previously

    2/25/25 7:14:46 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI downgraded by William Blair

    William Blair downgraded Tempus AI from Outperform to Mkt Perform

    2/12/25 7:11:34 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    TD Cowen resumed coverage on Tempus AI with a new price target

    TD Cowen resumed coverage of Tempus AI with a rating of Buy and set a new price target of $74.00 from $58.00 previously

    2/5/25 8:03:48 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Wolfe Research initiated coverage on Tempus AI with a new price target

    Wolfe Research initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $60.00

    12/13/24 8:31:40 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Guggenheim initiated coverage on Tempus AI with a new price target

    Guggenheim initiated coverage of Tempus AI with a rating of Buy and set a new price target of $74.00

    12/9/24 8:35:27 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI downgraded by Stifel with a new price target

    Stifel downgraded Tempus AI from Buy to Hold and set a new price target of $65.00 from $45.00 previously

    11/11/24 7:48:55 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Fukushima Ryan sold $461,606 worth of shares (5,000 units at $92.32) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    10/8/25 4:15:07 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    CEO and Chairman Lefkofsky Eric P sold $25,457,014 worth of shares (332,500 units at $76.56) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    9/29/25 4:33:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Director Epstein David R sold $18,410 worth of Class A Comnmon Stock (250 units at $73.64), decreasing direct ownership by 0.92% to 27,041 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    9/4/25 4:15:07 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Chief Operating Officer Fukushima Ryan sold $758,028 worth of shares (10,000 units at $75.80) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    9/4/25 4:15:11 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    CEO and Chairman Lefkofsky Eric P sold $24,637,581 worth of shares (332,500 units at $74.10) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    8/29/25 5:13:27 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Director Leonsis Theodore sold $1,516,600 worth of shares (20,000 units at $75.83) (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    8/28/25 4:15:09 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Amendment: Director Leonsis Theodore sold $3,075,600 worth of shares (44,000 units at $69.90) (SEC Form 4)

    4/A - Tempus AI, Inc. (0001717115) (Issuer)

    8/21/25 4:15:23 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    EVP and General Counsel Polovin Andrew sold $402,982 worth of shares (5,398 units at $74.65), decreasing direct ownership by 4% to 132,056 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    8/21/25 4:15:26 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    CEO and Chairman Lefkofsky Eric P sold $1,303,307 worth of shares (17,458 units at $74.65), decreasing direct ownership by 0.86% to 2,020,042 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    8/21/25 4:15:21 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    EVP & Chief Admin & Legal Off Phelps Erik sold $273,532 worth of shares (3,664 units at $74.65), decreasing direct ownership by 4% to 94,115 units (SEC Form 4)

    4 - Tempus AI, Inc. (0001717115) (Issuer)

    8/21/25 4:15:23 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI Inc. Financials

    Live finance-specific insights

    View All

    Tempus to Report Third Quarter 2025 Financial Results on November 4

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 5436492 USA & Canada: Toll-Free (800) 715-9871 United States: Toll (646) 307-1963 Live Webcast: https://edge.media-server.com/mmc/p/vg3azega A

    10/21/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Announces the Acquisition of Paige

    Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin

    8/22/25 9:20:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report Second Quarter 2025 Financial Results on August 8

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7005219 Domestic Dial-in Number: (800) 715-9871 International Dial-in Numbe

    7/22/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus Reports First Quarter 2025 Results

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next

    5/6/25 4:01:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report First Quarter 2025 Financial Results on May 6

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4680302 Domestic Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307

    4/24/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report Fourth Quarter and Full Year 2024 Financial Results on February 24

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 9601821 Domestic Dial-in Number: (888) 596-4144 International Dial-i

    2/11/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report Third Quarter 2024 Financial Results on November 4

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the

    11/3/24 8:06:00 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report Third Quarter 2024 Financial Results on November 7

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7177136 Domestic Dial-in Number: (800) 715-9871 International Dial-in

    10/24/24 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus to Report Second Quarter 2024 Financial Results on August 6

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024. The company will hold the second quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 6326328 Domestic Dial-in Number: (800) 715-9871 International Dial-in

    7/17/24 9:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Tempus AI Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 5:00:02 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    11/12/24 4:30:28 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

    SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

    8/20/24 4:27:51 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Tempus AI Inc.

    SC 13G - Tempus AI, Inc. (0001717115) (Subject)

    8/8/24 4:38:12 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13D filed by Tempus AI Inc.

    SC 13D - Tempus AI, Inc. (0001717115) (Filed by)

    7/3/24 1:05:04 PM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology